Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

para-Methoxyamphetamine

From Wikipedia, the free encyclopedia
Chemical compound
Not to be confused with4-methylamphetamine or4-MA steroid.

Pharmaceutical compound
para-Methoxyamphetamine
Clinical data
Other namespara-Methoxyamphetamine;p-Methoxyamphetamine; PMA; 4-Methoxyamphetamine; 4-MA; 4-MeO-A
Routes of
administration
By mouth
Drug classSelective serotonin releasing agent (SSRA);Serotonergic psychedelic
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-(4-methoxyphenyl)propan-2-amine
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.000.525Edit this at Wikidata
Chemical and physical data
FormulaC10H15NO
Molar mass165.236 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1CC(C)N)OC
  • InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3 checkY
  • Key:NEGYEDYHPHMHGK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

para-Methoxyamphetamine (PMA), also known as4-methoxyamphetamine (4-MA), is adesigner drug of theamphetamine class withserotonergic effects.[2][3][4] Unlike other similar drugs of this family, PMA does not producestimulant,euphoriant, orentactogen effects,[5] and behaves more like anantidepressant in comparison,[6] though it does have somepsychedelic properties.[7][8]

PMA has been found intablets touted asMDMA (ecstasy)[9][10][11][12] although its effects are markedly different compared to those of MDMA. The consequences of such deception have often included hospitalization and death for unwitting users. PMA is commonly synthesized fromanethole, the flavor compound ofanise andfennel, mainly because the starting material for MDMA,safrole, has become less available due to law enforcement action, causing illicit drug manufacturers to use anethole as an alternative.[13]

Effects

[edit]

According toAlexander Shulgin inPiHKAL, the effects of PMA at doses of 50 to 80 mg includedhypertension,diethyltryptamine (DET)-reminiscent effects, distinctafter-images, and someparesthesia, "intoxication" oralcohol-likeintoxication, and nopsychedelic effects.[3][14] Inclinical studies, PMA produced "excitation, othercentral effects, andsympathomimetic effects, but similarly nopsychotomimetic effects.[14]Animal studies suggested that PMA would have partial psychedelic effects, but this did not seem to prove true in humans.[14] PMA only partially substituted for thepsychostimulantamphetamine indrug discrimination tests.[14][15][16] It did not substitute forMDMA in rodents, suggesting lack ofentactogenic effects.[15]

Adverse effects

[edit]

PMA has been associated with numerous adverse reactions including death.[17][18] Effects of PMA ingestion include many effects of the hallucinogenic amphetamines includingaccelerated andirregular heartbeat, blurred vision, and a strong feeling of intoxication that is often unpleasant. At high doses unpleasant effects such asnausea andvomiting, severehyperthermia andhallucinations may occur. The effects of PMA also seem to be much more unpredictable and variable between individuals than those of MDMA, and sensitive individuals may die from a dose of PMA by which a less susceptible person might only be mildly affected.[19] While PMA alone may cause significant toxicity, the combination of PMA with MDMA has a synergistic effect that seems to be particularly hazardous.[20] Since PMA has a slow onset of effects, several deaths have occurred where individuals have taken a pill containing PMA, followed by a pill containing MDMA some time afterwards due to thinking that the first pill was not active.[21]

Overdose

[edit]

PMA overdose can be a serious medical emergency that may occur at only slightly above the usual recreational dose range, especially if PMA is mixed with other stimulant drugs such as cocaine or MDMA. Characteristic symptoms are pronouncedhyperthermia,tachycardia, andhypertension, along with agitation, confusion, andconvulsions. PMA overdose also tends to causehypoglycaemia andhyperkalaemia, which can help to distinguish it from MDMA overdose. Complications can sometimes include more serious symptoms such asrhabdomyolysis andcerebral hemorrhage, requiring emergency surgery. There is no specific antidote, so treatment is symptomatic, and usually includes both external cooling, and internal cooling via IV infusion of cooled saline.Benzodiazepines are used initially to control convulsions, with stronger anticonvulsants such asphenytoin orthiopental used if convulsions continue. Blood pressure can be lowered either with a combination ofalpha blockers andbeta blockers (or a mixed alpha/beta blocker), or with other drugs such asnifedipine ornitroprusside.Serotonin antagonists anddantrolene may be used as required. Despite the seriousness of the condition, the majority of patients survive if treatment is given in time, however, patients with a core body temperature over 40 °C at presentation tend to have a poor prognosis.[22]

Pharmacology

[edit]

Pharmacodynamics

[edit]
Monoamine release ofPMATooltip para-methoxyamphetamine and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound5-HTTooltip SerotoninNETooltip NorepinephrineDATooltip DopamineRef
d-Amphetamine698–1,7656.6–7.25.8–24.8[23][24]
d-Methamphetamine736–1,29212.3–13.88.5–24.5[23][25]
2-MethoxyamphetamineND4731,478[26]
3-MethoxyamphetamineND58.0103[26]
para-Methoxyamphetamine (PMA)ND166867[26][27]
PMMATooltip para-MethoxymethamphetamineNDNDNDND
  (S)-PMMA411471,000[15][28][27]
  (R)-PMMA134>14,0001,600[15][28][27]
4-Methylamphetamine (4-MA)53.422.244.1[29][30][26]
4-Methylmethamphetamine (4-MMA)67.466.941.3[31][32]
para-Chloroamphetamine (PCA)28.323.5–26.242.2–68.5[30][26][33][34]
para-Chloromethamphetamine (PCMA)29.936.554.7[33][34]
Methedrone (4-MeO-MC)120–195111506–881[35][36][37][38][39]
Mephedrone (4-MMC)118.3–12258–62.749.1–51[25][24][36][38][39]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. Theassays were done in rat brainsynaptosomes and humanpotencies may be different. See alsoMonoamine releasing agent § Activity profiles for a larger table with more compounds.Refs:[40][41]

PMA acts as aselective serotonin releasing agent (SSRA) with weak effects ondopamine andnorepinephrine transporters.[42][43][44][45] ItsEC50Tooltip half-maximal effective concentration values for induction ofmonoamine release are 166 nM fordopamine and 867 nM fornorepinephrine in rat brainsynaptosomes, whereasserotonin was not reported.[26][27] The drug has been found to robustly increase brainserotonin levels and to weakly increase braindopamine levels in rodentsin vivo.[46] Relative toMDMA, PMA appears to be considerably less effective as a releaser of serotonin, with properties more akin to aserotonin reuptake inhibitor in comparison.[47]

PMA has also been shown to act as a potentmonoamine oxidase inhibitor (MAOI), specifically as areversibleinhibitor of theenzymemonoamine oxidase A (MAO-A) with no significant effects onmonoamine oxidase B (MAO-B).[48][49] TheIC50Tooltip half-maximal inhibitory concentration of PMA for MAO-A inhibition has been reported to be 300 to 600 nM.[50]

PMA shows very lowaffinities for theserotonin5-HT1A,5-HT2A, and5-HT2C receptors.[45] Its affinities (Ki) for these receptors have been reported to be >20,000 nM, 11,200 nM, and >13,000 nM, respectively.[45] In another earlier study, PMA similarly showed very weak affinity forserotonin receptors, including the serotonin5-HT1 and5-HT2 receptors (Ki = 79,400 nM and 33,600 nM, respectively).[51][52] On the other hand, PMA shows much higher affinities for the mouse and rattrace amine-associated receptor 1 (TAAR1).[45]

PMA evokes robusthyperthermia in rodents while producing only modesthyperactivity andserotonergic neurotoxicity, substantially lower than that caused by MDMA, and only at very high doses.[43][44][47] Accordingly, it is notself-administered by rodents unlikeamphetamine and MDMA.[5] Anecdotal reports by humans suggest it is not particularlyeuphoric at all, perhaps evendysphoric in contrast.[citation needed]

It appears that PMA elevates body temperatures dramatically; the cause of this property is suspected to be related to its ability to inhibit MAO-A and at the same time releasing large amounts of serotonin, effectively causingserotonin syndrome.[47][49] Amphetamines, especially serotonergic analogues such as MDMA, are stronglycontraindicated to take with MAOIs. Many amphetamines and adrenergic compounds raise body temperatures, whereas some tend to produce more euphoric activity or peripheral vasoconstriction, and may tend to favor one effect over another. It appears that PMA activates thehypothalamus much more strongly than MDMA and other drugs like ephedrine, thereby causing rapid increases in body temperature (which is the major cause of death in PMA mortalities).[53][54][55] Many people taking PMA try to get rid of the heat by taking off their clothes, taking cold showers or wrapping themselves in wet towels, and even sometimes by shaving off their hair.[56]

History

[edit]

PMA first came into circulation in the early 1970s, where it was used intentionally as a substitute for the hallucinogenic properties ofLSD.[3] It went by the street names of "Chicken Powder" and "Chicken Yellow" and was found to be the cause of a number of drug overdose deaths (the dosages taken being in the range of hundreds of milligrams) in the United States and Canada from that time.[57] Between 1974 and the mid-1990s, there appear to have been no known fatalities from PMA.[58]

Several deaths reported as MDMA-induced inAustralia in the mid-1990s are now considered to have been caused by PMA, the users unaware that they were ingesting PMA and not MDMA as they had intended.[12] There have been a number of PMA-induced deaths around the world since then.[59][60]

In July 2013, seven deaths in Scotland were linked to tablets containing PMA that had been mis-sold as ecstasy and which had theRolex crown logo on them.[10] Several deaths in Northern Ireland, Particularly East Belfast were also linked to "Green Rolex" pills during that month.[61]

In 2014, 2015 and early 2016, PMA sold as ecstasy was the cause of more deaths in the United States, United Kingdom,Netherlands, and Argentina. The pills containing the drug were reported to be red triangular tablets with a "Superman" logo.[11][62][63][64]

The Red Ferarri pills are a new press of theSuperman logo tablets that were reported to be found in Germany and Norway from 2016 to 2017.[65]

Society and culture

[edit]

Legal status

[edit]

International

[edit]

PMA is a Schedule I drug under theConvention on Psychotropic Substances.[66]

Australia

[edit]

PMA is considered a Schedule 9 prohibited substance in Australia under thePoisons Standard (October 2015).[67] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[67]

Finland

[edit]

Substance is scheduled in decree of the government on amending the government decree on substances, preparations and plants considered to be narcotic drugs.[68][69]

Germany

[edit]

PMA is part of the Appendix 1 of theBetäubungsmittelgesetz. Therefore, owning and distribution of PMA is illegal.

Netherlands

[edit]

On 13 June 2012Edith Schippers, Dutch Minister of Health, Welfare and Sport, revoked the legality of PMA in theNetherlands after five deaths were reported in that year.[70]

United Kingdom

[edit]

PMA is a Class A drug in the UK.[71]

United States

[edit]

PMA is classified as aSchedule Ihallucinogen under theControlled Substances Act in theUnited States.[72]

Economics

[edit]

Distribution

[edit]

Because PMA is given out through the same venues and distribution channels that MDMA tablets are, the risk of being severely injured, hospitalized or even dying from use of ecstasy increases significantly when a batch of ecstasy pills containing PMA starts to be sold in a particular area.[73] PMA pills could be a variety of colours or imprints, and there is no way of knowing just from the appearance of a pill what drug(s) it might contain.[74][75] Notable batches of pills containing PMA have included Louis Vuitton,[76] Mitsubishi Turbo, Blue Transformers, Red/Blue Mitsubishi and Yellow Euro pills. Also PMA has been found in powder form.[77]

Analogues

[edit]

Four analogues of PMA have been reported to be sold on the black market, includingPMMA,PMEA,[78]4-ETA and4-MTA. These are the N-methyl, N-ethyl, 4-ethoxy and 4-methylthio analogues of PMA, respectively. PMMA and PMEA are anecdotally weaker, more "ecstasy-like" and somewhat less dangerous than PMA itself, but can still produce nausea and hyperthermia similar to that produced by PMA, albeit at slightly higher doses.4-EtOA was briefly sold in Canada in the 1970s, but little is known about it.[3] 4-MTA, however, is even more dangerous than PMA and produces strong serotonergic effects and intense hyperthermia, but with little to no euphoria, and was implicated in several deaths in the late 1990s.

See also

[edit]

References

[edit]
  1. ^Anvisa (2023-07-24)."RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-07-25).Archived from the original on 2023-08-27. Retrieved2023-08-27.
  2. ^Drug Enforcement Administration October 2000.The Hallucinogen PMA: Dancing With DeathArchived 2007-12-04 at theWayback Machine
  3. ^abcdShulgin AT, Shulgin A (1991)."#97 4-MA".Pihkal: A Chemical Love Story. Transform Press.ISBN 978-0-9630096-0-9.Archived from the original on 2007-04-08. Retrieved2005-12-11.
  4. ^Karlis S (7 April 2008)."Warning of possible shift to killer drug".Sydney Morning Herald. Fairfax.Archived from the original on 2008-07-02. Retrieved2008-06-29.
  5. ^abCorrigall WA, Robertson JM, Coen KM, Lodge BA (January 1992). "The reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine".Pharmacology, Biochemistry, and Behavior.41 (1):165–169.CiteSeerX 10.1.1.670.6929.doi:10.1016/0091-3057(92)90077-S.PMID 1539067.S2CID 30080516.
  6. ^Preve M, Suardi NE, Godio M, Traber R, Colombo RA (April 2017). "Paramethoxymethamphetamine (Mitsubishi turbo) abuse: Case report and literature review".European Psychiatry.41 (S1): s875.doi:10.1016/j.eurpsy.2017.01.1762.S2CID 148876431.
  7. ^Hegadoren KM, Martin-Iverson MT, Baker GB (April 1995). "Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine".Psychopharmacology.118 (3):295–304.doi:10.1007/BF02245958.PMID 7617822.S2CID 30756295.
  8. ^Winter JC (February 1984). "The stimulus properties of para-methoxyamphetamine: a nonessential serotonergic component".Pharmacology, Biochemistry, and Behavior.20 (2):201–203.doi:10.1016/0091-3057(84)90242-9.PMID 6546992.S2CID 9673028.
  9. ^"EcstasyData.org: Results : Lab Test Results for Recreational Drugs".www.ecstasydata.org.Archived from the original on 2015-02-15. Retrieved2015-02-15.
  10. ^abDavies C (10 July 2013)."Warning over fake ecstasy tablets after seven people die in Scotland".The Guardian.Archived from the original on 2 February 2020. Retrieved10 July 2013.
  11. ^abBarrell R (2 January 2015)."Four Dead Amid Fears Of Dodgy Batch Of 'Superman' Ecstasy Hitting The UK".HuffPost UK.Archived from the original on 21 April 2022. Retrieved12 June 2022.
  12. ^abByard RW, Gilbert J, James R, Lokan RJ (September 1998). "Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit?".The American Journal of Forensic Medicine and Pathology.19 (3):261–265.doi:10.1097/00000433-199809000-00013.PMID 9760094.
  13. ^Waumans D, Bruneel N, Tytgat J (April 2003). "Anise oil as para-methoxyamphetamine (PMA) precursor".Forensic Science International.133 (1–2):159–170.doi:10.1016/S0379-0738(03)00063-X.PMID 12742705.
  14. ^abcdShulgin A, Manning T, Daley P (2011).The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley:Transform Press.ISBN 978-0-9630096-3-0. Retrieved2 November 2024.
  15. ^abcdGlennon RA (April 2017)."The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse".J Med Chem.60 (7):2605–2628.doi:10.1021/acs.jmedchem.7b00085.PMC 5824997.PMID 28244748.Table 5. Action of MDMA, MDA, and PMMA as Releasing Agents at the Serotonin (SERT), Dopamine (DAT), and Norepinephrine (NET) Transporters18,59,60 [...]a Data, although from different publications, were obtained from the same laboratory.
  16. ^Glennon RA, Young R, Hauck AE (May 1985). "Structure-activity studies on methoxy-substituted phenylisopropylamines using drug discrimination methodology".Pharmacol Biochem Behav.22 (5):723–729.doi:10.1016/0091-3057(85)90520-9.PMID 3839309.
  17. ^Martin TL (October 2001)."Three cases of fatal paramethoxyamphetamine overdose".Journal of Analytical Toxicology.25 (7):649–651.doi:10.1093/jat/25.7.649.PMID 11599618.
  18. ^Becker J, Neis P, Röhrich J, Zörntlein S (March 2003). "A fatal paramethoxymethamphetamine intoxication".Legal Medicine.5 (Suppl 1):S138 –S141.doi:10.1016/s1344-6223(02)00096-2.PMID 12935573.
  19. ^Smets G, Bronselaer K, De Munnynck K, De Feyter K, Van de Voorde W, Sabbe M (August 2005). "Amphetamine toxicity in the emergency department".European Journal of Emergency Medicine.12 (4):193–197.doi:10.1097/00063110-200508000-00010.PMID 16034267.S2CID 40206693.
  20. ^Lora-Tamayo C, Tena T, Rodríguez A, Moreno D, Sancho JR, Enseñat P, et al. (March 2004). "The designer drug situation in Ibiza".Forensic Science International.140 (2–3):195–206.doi:10.1016/j.forsciint.2003.11.021.PMID 15036441.
  21. ^Dams R, De Letter EA, Mortier KA, Cordonnier JA, Lambert WE, Piette MH, et al. (1 July 2003)."Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study".Journal of Analytical Toxicology.27 (5):318–322.doi:10.1093/jat/27.5.318.PMID 12908947.
  22. ^Caldicott DG, Edwards NA, Kruys A, Kirkbride KP, Sims DN, Byard RW, et al. (2003). "Dancing with "death": p-methoxyamphetamine overdose and its acute management".Journal of Toxicology. Clinical Toxicology.41 (2):143–154.doi:10.1081/CLT-120019130.PMID 12733852.S2CID 39578828.
  23. ^abRothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin".Synapse.39 (1):32–41.doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.PMID 11071707.
  24. ^abBaumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013)."Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products".Neuropsychopharmacology.38 (4):552–562.doi:10.1038/npp.2012.204.PMC 3572453.PMID 23072836.
  25. ^abBaumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012)."The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue".Neuropsychopharmacology.37 (5):1192–1203.doi:10.1038/npp.2011.304.PMC 3306880.PMID 22169943.
  26. ^abcdefBlough B (July 2008)."Dopamine-releasing agents"(PDF). In Trudell ML, Izenwasser S (eds.).Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320.ISBN 978-0-470-11790-3.OCLC 181862653.OL 18589888W.
  27. ^abcdVekariya R (2012).Towards Understanding the Mechanism of Action of Abused Cathinones (Master of Science thesis). Virginia Commonwealth University.doi:10.25772/AR93-7024 – via VCU Theses and Dissertations.
  28. ^abGlennon RA, Young R (5 August 2011). "Drug Discrimination and Mechanisms of Drug Action".Drug Discrimination. Wiley. pp. 183–216.doi:10.1002/9781118023150.ch6.ISBN 978-0-470-43352-2.PMMA is a 5-HT releasing agent. S(+)PMMA is a potent releaser of 5-HT (EC50 = 41 nM) and NE (EC50 = 147 nM) with reduced activity as a releaser of DA (EC50 = 1,000 nM); the R(−)isomer of PMMA is a releaser of 5-HT (EC50 = 134 nM) with reduced potency for release of NE (EC50 = 1,600 nM) and DA (EC50 > 14,000 nM) (R.B. Rothman, unpublished data).
  29. ^Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (May 2005). "Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs".The Journal of Pharmacology and Experimental Therapeutics.313 (2):848–854.doi:10.1124/jpet.104.080101.PMID 15677348.S2CID 12135483.
  30. ^abForsyth AN (22 May 2012)."Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines".ScholarWorks@UNO. Retrieved4 November 2024.
  31. ^Solis E, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, et al. (September 2017)."N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability".Neuropsychopharmacology.42 (10):1950–1961.doi:10.1038/npp.2017.98.PMC 5561352.PMID 28530234.
  32. ^Sakloth F (11 December 2015).Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action.Theses and Dissertations (Ph.D. thesis). Virginia Commonwealth University.doi:10.25772/AY8R-PW77. Retrieved24 November 2024 – via VCU Scholars Compass.
  33. ^abFitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, et al. (March 2024)."Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones".Neuropharmacology.245 109827.doi:10.1016/j.neuropharm.2023.109827.PMC 10842458.PMID 38154512.
  34. ^abNicole L (2022).In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones (Ph.D. thesis). The University of Arkansas for Medical Sciences.ProQuest 2711781450. Retrieved5 December 2024.FIGURE 2-6: Release: Effects of the specified test drug on monoamine release by DAT (red circles), NET (blue squares), and SERT (black traingles) in rat brain tissue. [...] EC50 values determined for the drug indicated within the panel. [...]
  35. ^Baumann MH, Walters HM, Niello M, Sitte HH (2018)."Neuropharmacology of Synthetic Cathinones".Handb Exp Pharmacol. Handbook of Experimental Pharmacology.252:113–142.doi:10.1007/164_2018_178.ISBN 978-3-030-10560-0.PMC 7257813.PMID 30406443.
  36. ^abBlough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019)."The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes".Psychopharmacology.236 (3):915–924.doi:10.1007/s00213-018-5063-9.PMC 6475490.PMID 30341459.
  37. ^Shalabi AR (14 December 2017).Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters.Theses and Dissertations (Ph.D. thesis). Virginia Commonwealth University.doi:10.25772/M4E1-3549. Retrieved24 November 2024 – via VCU Scholars Compass.
  38. ^abWalther D, Shalabi AR, Baumann MH, Glennon RA (January 2019)."Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents".ACS Chem Neurosci.10 (1):740–745.doi:10.1021/acschemneuro.8b00524.PMC 8269283.PMID 30354055.
  39. ^abBonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, et al. (May 2015)."Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues".Br J Pharmacol.172 (10):2433–2444.doi:10.1111/bph.13030.PMC 4409897.PMID 25438806.
  40. ^Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs".Eur J Pharmacol.479 (1–3):23–40.doi:10.1016/j.ejphar.2003.08.054.PMID 14612135.
  41. ^Rothman RB, Baumann MH (2006)."Therapeutic potential of monoamine transporter substrates".Current Topics in Medicinal Chemistry.6 (17):1845–1859.doi:10.2174/156802606778249766.PMID 17017961.
  42. ^Menon MK, Tseng LF,Loh HH (May 1976)."Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines".The Journal of Pharmacology and Experimental Therapeutics.197 (2):272–279.doi:10.1016/S0022-3565(25)30506-9.PMID 946817.
  43. ^abHitzemann RJ, Loh HH, Domino EF (October 1971). "Effect of para-methoxyamphetamine on catecholamine metabolism in the mouse brain".Life Sciences.10 (19 Pt. 1):1087–1095.doi:10.1016/0024-3205(71)90227-x.PMID 5132700.
  44. ^abTseng LF, Menon MK, Loh HH (May 1976)."Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue".The Journal of Pharmacology and Experimental Therapeutics.197 (2):263–271.doi:10.1016/S0022-3565(25)30505-7.PMID 1271280.
  45. ^abcdSimmler LD, Rickli A, Hoener MC, Liechti ME (April 2014). "Monoamine transporter and receptor interaction profiles of a new series of designer cathinones".Neuropharmacology.79:152–160.doi:10.1016/j.neuropharm.2013.11.008.PMID 24275046.
  46. ^Matsumoto T, Maeno Y, Kato H, Seko-Nakamura Y, Monma-Ohtaki J, Ishiba A, et al. (August 2014). "5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis".Eur Neuropsychopharmacol.24 (8):1362–1370.doi:10.1016/j.euroneuro.2014.04.009.PMID 24862256.
  47. ^abcDaws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F (August 2000). "Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat".Progress in Neuro-Psychopharmacology & Biological Psychiatry.24 (6):955–977.doi:10.1016/S0278-5846(00)00113-5.PMID 11041537.S2CID 24347904.
  48. ^Green AL, El Hait MA (April 1980). "p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo".The Journal of Pharmacy and Pharmacology.32 (4):262–266.doi:10.1111/j.2042-7158.1980.tb12909.x.PMID 6103055.S2CID 42213032.
  49. ^abAsk AL, Fagervall I, Ross SB (September 1983). "Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain".Naunyn-Schmiedeberg's Archives of Pharmacology.324 (2):79–87.doi:10.1007/BF00497011.PMID 6646243.S2CID 403633.
  50. ^Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019)."Amphetamine Derivatives as Monoamine Oxidase Inhibitors".Front Pharmacol.10 1590.doi:10.3389/fphar.2019.01590.PMC 6989591.PMID 32038257.
  51. ^Glennon RA (January 1987). "Central serotonin receptors as targets for drug research".J Med Chem.30 (1):1–12.doi:10.1021/jm00384a001.PMID 3543362.Table II. Affinities of Selected Phenalkylamines for 5-HT1 and 5-HT2 Binding Sites
  52. ^Shannon M, Battaglia G, Glennon RA, Titeler M (June 1984). "5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)".Eur J Pharmacol.102 (1):23–29.doi:10.1016/0014-2999(84)90333-9.PMID 6479216.
  53. ^Jaehne EJ, Salem A, Irvine RJ (July 2005). "Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation".Pharmacology, Biochemistry, and Behavior.81 (3):485–496.doi:10.1016/j.pbb.2005.04.005.PMID 15904952.S2CID 9680452.
  54. ^Callaghan PD, Irvine RJ, Daws LC (October 2005). "Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry".Neurochemistry International.47 (5):350–361.doi:10.1016/j.neuint.2005.04.026.PMID 15979209.S2CID 23372945.
  55. ^Jaehne EJ, Salem A, Irvine RJ (September 2007). "Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia".Psychopharmacology.194 (1):41–52.doi:10.1007/s00213-007-0825-9.PMID 17530474.S2CID 25420902.
  56. ^Refstad S (November 2003)."Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects".Acta Anaesthesiologica Scandinavica.47 (10):1298–1299.doi:10.1046/j.1399-6576.2003.00245.x.PMID 14616331.S2CID 28006785.
  57. ^DEA."The Hallucinogen PMA: Dancing With Death"(PDF).Archived(PDF) from the original on 2008-06-23. Retrieved2008-06-29.
  58. ^Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC (1 March 1998)."Recent paramethoxyamphetamine deaths".Journal of Analytical Toxicology.22 (2):169–172.doi:10.1093/jat/22.2.169.PMID 9547415.
  59. ^Galloway JH, Forrest AR (September 2002). "Caveat Emptor: Death involving the use of 4-methoxyamphetamine".Journal of Clinical Forensic Medicine.9 (3): 160.doi:10.1016/S1353-1131(02)00043-3.PMID 15274949.
  60. ^Lamberth PG, Ding GK, Nurmi LA (April 2008). "Fatal paramethoxy-amphetamine (PMA) poisoning in the Australian Capital Territory".The Medical Journal of Australia.188 (7): 426.doi:10.5694/j.1326-5377.2008.tb01695.x.PMID 18393753.S2CID 11987961.
  61. ^"Renewed warning over 'Rolex' pills".BBC News. 24 July 2013.Archived from the original on 11 September 2018. Retrieved10 September 2018.
  62. ^"WATCH OUT FOR DANGEROUS SUPERMAN PILL - News - Deep House Amsterdam".deephouseamsterdam.com. 30 January 2014.Archived from the original on 2 January 2015. Retrieved2 January 2015.
  63. ^"¿Qué es Superman, la droga que ya ha cobrado varias vidas en el mundo?" [What is Superman, the drug that has already claimed several lives in the world?].ElPais [The Country] (in Spanish). 18 April 2016.Archived from the original on 19 April 2016. Retrieved19 April 2016.
  64. ^"Las claves para entender qué pasó".La Nación. 2016-04-17.Archived from the original on 2016-04-18. Retrieved2016-04-19.
  65. ^"Drug Warning – Reagent Tests UK".www.reagent-tests.uk.Archived from the original on 2018-09-11. Retrieved2017-07-05.
  66. ^"Annual Estimates Of Requirements Of Narcotic Drugs, Manufacture Of Synthetic Drugs, Opium Production And Cultivation Of The…"(PDF). Archived fromthe original(PDF) on 2012-08-31. Retrieved2008-06-15.
  67. ^abPoisons Standard October 2015https://www.comlaw.gov.au/Details/F2015L01534Archived 2016-01-19 at theWayback Machine
  68. ^"Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista annetun valtioneuvoston asetuksen muuttamisesta" [Decree of the Government on amending the government decree on substances, preparations and plants considered to be narcotic drugs].Finlex (in Finnish). Helsinki: Finland's Ministry of Justice. 25 October 2018.Archived from the original on 26 March 2023. Retrieved8 April 2023.
  69. ^"Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista annetun valtioneuvoston asetuksen muuttamisesta" [Decree of the Government on amending the government decree on substances, preparations and plants considered to be narcotic drugs].Finlex (in Finnish). Helsinki: Finland's Ministry of Justice. 13 January 2022.Archived from the original on 24 March 2023. Retrieved8 April 2023.
  70. ^"Doden na gebruik speed met 4-MA" [Deaths after using speed 4-MA] (in Dutch). 13 June 2012.Archived from the original on 16 June 2012. Retrieved13 June 2012.
  71. ^"List of Controlled Drugs".Release (agency). 2013-08-13.Archived from the original on 2024-04-29. Retrieved2024-04-29.
  72. ^21 CFR1308.11Archived 2009-08-27 at theWayback Machine
  73. ^Galloway JH, Forrest AR (September 2002). "Caveat Emptor: Death involving the use of 4-methoxyamphetamine".Journal of Clinical Forensic Medicine.9 (3): 160.doi:10.1016/s1353-1131(02)00043-3.PMID 15274949.
  74. ^"Drug Info". Archived fromthe original on 2008-05-29. Retrieved2008-06-15.
  75. ^"Warning: pills sold as ecstasy found to contain PMA".Archived from the original on 2008-06-22. Retrieved2008-06-15.
  76. ^Chamberlin T, Murray D. NET Syndicated QLD News'Louis Vuitton' designer death drug hits the streetsArchived 2012-09-28 at theWayback Machine
  77. ^Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ (October 2001)."Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA)".Journal of Analytical Toxicology.25 (7):645–648.doi:10.1093/jat/25.7.645.PMID 11599617.
  78. ^Casale JF, Hays PA, Spratley TK, Smith PR (2006). "The Characterization of 4-Methoxy-N-ethylamphetamine Hydrochloride".Microgram Journal.4 (1–4):42–46.

External links

[edit]
Wikimedia Commons has media related to4-Methoxyamphetamine.
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Non-specific
AAADTooltip Aromatic L-amino acid decarboxylase
MAOTooltip Monoamine oxidase
Phenethylamines
(dopamine,epinephrine,
norepinephrine)
PAHTooltip Phenylalanine hydroxylase
THTooltip Tyrosine hydroxylase
DBHTooltip Dopamine beta-hydroxylase
PNMTTooltip Phenylethanolamine N-methyltransferase
COMTTooltip Catechol-O-methyl transferase
Tryptamines
(serotonin,melatonin)
TPHTooltip Tryptophan hydroxylase
AANATTooltip Serotonin N-acetyl transferase
ASMTTooltip Acetylserotonin O-methyltransferase
Histamine
HDCTooltip Histidine decarboxylase
HNMTTooltip Histamine N-methyltransferase
DAOTooltip Diamine oxidase
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Para-Methoxyamphetamine&oldid=1307242271"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp